PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors is a research paper published in Exploration of Targeted Anti-tumor Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R21CA223371
National Institutes of Health
Grant: R01CA242003
National Institutes of Health
Grant: R01AG063801
National Institutes of Health
Grant: R01CA241191
European Commission
Grant: 242003
NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE
National Institutes of Health
Grant: 5R01CA241191-03
Inhibition of Bcl-xL by Targeted Degradation
National Institutes of Health
Grant: 5R01CA242003-03
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer
National Institutes of Health
Grant: 5R01AG063801-03
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics
National Institutes of Health
Grant: 5R21CA223371-02
NCI Clinical and Translational Exploratory/ Developmental Studies
FWCI
0.89
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals